Arcus Biosciences (NYSE:RCUS) CEO Sells $633,360.36 in Stock

by · The Cerbat Gem

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) CEO Terry Rosen sold 28,947 shares of Arcus Biosciences stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $633,360.36. Following the completion of the transaction, the chief executive officer owned 2,220,553 shares in the company, valued at $48,585,699.64. The trade was a 1.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Arcus Biosciences Trading Down 1.2%

NYSE RCUS traded down $0.26 during mid-day trading on Thursday, hitting $22.02. The company’s stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The firm has a market capitalization of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The stock’s fifty day simple moving average is $20.82 and its two-hundred day simple moving average is $13.98.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The company’s revenue was down 45.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.00) earnings per share. Research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RCUS shares. Wells Fargo & Company boosted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. HC Wainwright increased their target price on Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Finally, The Goldman Sachs Group increased their price objective on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $28.89.

Read Our Latest Stock Report on Arcus Biosciences

Institutional Trading of Arcus Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank grew its stake in Arcus Biosciences by 3.9% during the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock worth $266,000 after buying an additional 736 shares during the last quarter. Creative Planning boosted its holdings in shares of Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after acquiring an additional 771 shares during the period. GAMMA Investing LLC grew its position in shares of Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after acquiring an additional 1,021 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Arcus Biosciences by 8.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock valued at $142,000 after purchasing an additional 1,294 shares during the period. Finally, Parallel Advisors LLC raised its holdings in shares of Arcus Biosciences by 1.6% during the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock valued at $716,000 after buying an additional 1,422 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Featured Stories